Australian Pesticides and Veterinary Medicines Authority

Global Veterinary Oncology Market to Surpass US$ 1,356.1 Million by 2030 - Coherent Market Insights

Retrieved on: 
Friday, September 16, 2022
Science, Adoption, Sale, Food, Australian Pesticides and Veterinary Medicines Authority, Growth, Government, North Carolina State University College of Veterinary Medicine, Elbow, Analysis, Pesticide, APVMA, US, Research, US Food Sovereignty Alliance, Pharmaceutical industry, Animal, Dog, CAGR, Vaccine, Morphogenesis

SEATTLE, Sept. 16, 2022 /PRNewswire/ --According to Coherent Market Insights, the global veterinary oncology market is estimated to be valued at US$ 592.8 million in 2022 and is expected to exhibit a CAGR of 10.9 % during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, Sept. 16, 2022 /PRNewswire/ --According to Coherent Market Insights, the global veterinary oncology market is estimated to be valued at US$ 592.8 million in 2022 and is expected to exhibit a CAGR of 10.9 % during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Veterinary Oncology Market:
    Major players operating in the market are focused on getting the approval by the regulatory bodies and launching new drug in the market, which is expected to drive the global veterinary oncology market growth over the forecast period.
  • Asia Pacific is expected to witness a rapid growth in the global veterinary oncology market during the forecast period, owing to the presence of various veterinary foundations focusing on veterinary cancer research.
  • The foundation also supports Australian Comparative Oncology Consortium, consisting of Australian veterinary oncology specialists who collaborate to develop novel therapies.

Global Veterinary Oncology Market to Surpass US$ 1,356.1 Million by 2030 - Coherent Market Insights

Retrieved on: 
Friday, September 16, 2022
Science, Adoption, Sale, Food, Australian Pesticides and Veterinary Medicines Authority, Growth, Government, North Carolina State University College of Veterinary Medicine, Elbow, Analysis, Pesticide, APVMA, US, Research, US Food Sovereignty Alliance, Pharmaceutical industry, Animal, Dog, CAGR, Vaccine, Morphogenesis

SEATTLE, Sept. 16, 2022 /PRNewswire/ --According to Coherent Market Insights, the global veterinary oncology market is estimated to be valued at US$ 592.8 million in 2022 and is expected to exhibit a CAGR of 10.9 % during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, Sept. 16, 2022 /PRNewswire/ --According to Coherent Market Insights, the global veterinary oncology market is estimated to be valued at US$ 592.8 million in 2022 and is expected to exhibit a CAGR of 10.9 % during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Veterinary Oncology Market:
    Major players operating in the market are focused on getting the approval by the regulatory bodies and launching new drug in the market, which is expected to drive the global veterinary oncology market growth over the forecast period.
  • Asia Pacific is expected to witness a rapid growth in the global veterinary oncology market during the forecast period, owing to the presence of various veterinary foundations focusing on veterinary cancer research.
  • The foundation also supports Australian Comparative Oncology Consortium, consisting of Australian veterinary oncology specialists who collaborate to develop novel therapies.

Panaxia and Neuraxpharm - the first in Europe to sell medical cannabis extracts for vaporization

Retrieved on: 
Wednesday, December 8, 2021
Central nervous system, Physician, Pharmacy, Database, Smoking, McNeil Consumer Healthcare, Publication, Prescription, Growth, Smoke, Patient, CEO, Inhalation, ANSM, Method, Partnership, Permira, TASE, LL, TEL, EU, CNS, Absorption, Probiotic, Marketing, Doctor of Philosophy, Chlorophyll, Australian Pesticides and Veterinary Medicines Authority, Pharmaceutical industry, Drug, Generic drug, Tourism

Thus, both companies became the first and only companies in the world to market medical cannabis extracts which may be used for vaporization in Europe.

Key Points: 
  • Thus, both companies became the first and only companies in the world to market medical cannabis extracts which may be used for vaporization in Europe.
  • At the same time, we will keep on expanding our business all over Europe, registering our products in appropriate regulatory routes".
  • Dr. Jrg-Thomas Dierks, CEO of Neuraxpharm: "With the first sales of medical cannabis extracts which may be used for vaporization in Germany, we have reached another milestone in our successful partnership with Panaxia.
  • Above all, I am delighted that we can now offer our patients in Germany even more tailored treatment options with medical cannabis."

Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

Retrieved on: 
Thursday, September 2, 2021
Tetra, Company, SAA, TBP, Terminology, Legislation, Pain, Science, MAA, Insurance, Physician, View, Research, Forward-looking statement, THC, Inflammation, CBD, Multimedia, Safety, Marketing, News, Patient, FRA, Australian Pesticides and Veterinary Medicines Authority, TSX, FDA, Plasma protein binding, Drug development, Medicine, Pharmaceutical industry, Medical device

OTTAWA, ON, Sept. 2, 2021 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the"Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority.

Key Points: 
  • OTTAWA, ON, Sept. 2, 2021 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the"Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority.
  • Overall, the SAA Report provided positive feedback on Tetra's drug development plan for QIXLEEFand eligibility for submitting a Marketing Authorization Application (MAA) under Directive 2001/83/EC (Directive).
  • The SAA Report endorses Tetra's proposed plan to address the nonclinical safety requirements for submitting a MAA for QIXLEEF.
  • The SAA Report discusses the assessment of both the PLENITUDE and REBORN clinical programs with regards to a MAA.